← All trials
NCT06242470
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 6, 2024
- Primary completion
- May 31, 2028
- Completion date
- Oct 31, 2028
- First posted
- Feb 5, 2024
- Last posted
- Nov 25, 2024
- Enrollment
- 230
- Arms / groups
- 10 / —
- Source
- AACT · ctgov ingestion
Sponsors
- MacroGenicsLead sponsor
- MacroGenicsOfficial
Drugs studied
Indications studied
- Squamous Cell Carcinoma of Head and Neck
- Esophageal Squamous Cell Carcinoma
- Urinary Bladder Neoplasms
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Uterine Cervical Neoplasms
- Esophageal Neoplasms
- Carcinoma, Hepatocellular
- Melanoma
- Neoplasms
- Ovarian Neoplasms
- Pancreatic Neoplasms
- Sarcoma
- Stomach Neoplasms
- Colorectal Neoplasms
- Endometrial Neoplasms
- Small Cell Lung Carcinoma
- Prostatic Neoplasms, Castration-Resistant
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.